Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Centessa Pharmaceuticals Plc
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
NLS Pharma Group
Synchronicity Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Orexin 2 Receptor for rcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seltorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for rcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for rcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin-2 for rcolepsy and Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting
May 18, 2021: NLS Pharmaceutics announces new study data confirming Mazindol’s unique orexin pathway activation for treating rcolepsy
Mar 29, 2021: NLS Pharmaceutics announces issuance of Cadian Patent covering its novel formulation of controlled-release Mazindol (Mazindol CR)
Mar 10, 2021: FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia
Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Feb 04, 2021: Health Cada authorizes DAYVIGO (lemborexant)
Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020
Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Aug 28, 2020: Eisai presents new alyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020
Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)
Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Centessa Pharmaceuticals Plc, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Idorsia Pharmaceutical Ltd, 2021
Pipeline by Inexia Ltd, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by NLS Pharma Group, 2021
Pipeline by Synchronicity Pharma Inc, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Yangtze River Pharmaceutical Group, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021